Literature DB >> 24304919

DNA aptamers that target human glioblastoma multiforme cells overexpressing epidermal growth factor receptor variant III in vitro.

Yan Tan1, Yu-sheng Shi, Xi-dong Wu, Hui-yu Liang, Yu-bo Gao, Shu-ji Li, Xing-mei Zhang, Fang Wang, Tian-ming Gao.   

Abstract

AIM: Aptamers are oligonucleic acid or peptide molecules that bind to a specific target molecule in cells, thus may act as effective vehicles for drug or siRNA delivery. In this study we investigated the DNA aptamers that target human glioblastoma multiforme (GBM) cells overexpressing epidermal growth factor receptor variant III (EGFRvIII), which was linked to radiation and chemotherapeutic resistance of this most aggressive brain tumor.
METHODS: A 73-mer ssDNA library containing molecules with 30 nt of random sequence flanked by two primer hybridization sites was chosen as the initial library. Cell systematic evolution of ligands by exponential enrichment (Cell-SELEX) method was used to select the DNA aptamers that target EGFRvIII. The binding affinity of the aptamers was measured using a cell-based biotin-avidin ELISA.
RESULTS: After 14 rounds of selection, four DNA aptamers (32, 41, 43, and 47) that specifically bound to the EGFRvIII-overexpressing human glioma U87Δ cells with Kd values of less than 100 nmol/L were discovered. These aptamers were able to distinguish the U87Δ cells from the negative control human glioma U87MG cells and HEK293 cells. Aptamer 32 specifically bound to the EGFRvIII protein with an affinity similar to the EGFR antibody (Kd values of aptamer 32 and the EGFR antibody were 0.62±0.04 and 0.32±0.01 nmol/L, respectively), and this aptamer was localized in the cell nucleus.
CONCLUSION: The DNA aptamers are promising molecular probes for the diagnosis and treatment of GBM.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24304919      PMCID: PMC4002567          DOI: 10.1038/aps.2013.137

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  32 in total

1.  Aptamer-based bio-barcode assay for the detection of cytochrome-c released from apoptotic cells.

Authors:  Irene P M Lau; Erika K S Ngan; Jacky F C Loo; Y K Suen; H P Ho; S K Kong
Journal:  Biochem Biophys Res Commun       Date:  2010-04-14       Impact factor: 3.575

Review 2.  Functional aptamers and aptazymes in biotechnology, diagnostics, and therapy.

Authors:  Michael Famulok; Jörg S Hartig; Günter Mayer
Journal:  Chem Rev       Date:  2007-08-23       Impact factor: 60.622

3.  Bivalent aptamers deliver the punch.

Authors:  Jiehua Zhou; John J Rossi
Journal:  Chem Biol       Date:  2008-07-21

4.  Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.

Authors:  James O McNamara; Eran R Andrechek; Yong Wang; Kristi D Viles; Rachel E Rempel; Eli Gilboa; Bruce A Sullenger; Paloma H Giangrande
Journal:  Nat Biotechnol       Date:  2006-06-25       Impact factor: 54.908

5.  Expression of constitutively activated EGFRvIII in non-small cell lung cancer.

Authors:  Isamu Okamoto; Lawrence C Kenyon; David R Emlet; Takeshi Mori; Ji-ichiro Sasaki; Susumu Hirosako; Yasuko Ichikawa; Hiroto Kishi; Andrew K Godwin; Masakazu Yoshioka; Moritaka Suga; Mitsuhiro Matsumoto; Albert J Wong
Journal:  Cancer Sci       Date:  2003-01       Impact factor: 6.716

6.  Protein phosphatase activity of PTEN inhibited the invasion of glioma cells with epidermal growth factor receptor mutation type III expression.

Authors:  Xiu-Mei Cai; Bei-Bei Tao; Li-Ying Wang; Yu-Long Liang; Jia-Wei Jin; Yong Yang; Ya-Li Hu; Xi-Liang Zha
Journal:  Int J Cancer       Date:  2005-12-20       Impact factor: 7.396

Review 7.  Malignant astrocytic glioma: genetics, biology, and paths to treatment.

Authors:  Frank B Furnari; Tim Fenton; Robert M Bachoo; Akitake Mukasa; Jayne M Stommel; Alexander Stegh; William C Hahn; Keith L Ligon; David N Louis; Cameron Brennan; Lynda Chin; Ronald A DePinho; Webster K Cavenee
Journal:  Genes Dev       Date:  2007-11-01       Impact factor: 11.361

8.  Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma.

Authors:  Christopher E Pelloski; Karla V Ballman; Alfred F Furth; Li Zhang; E Lin; Erik P Sulman; Krishna Bhat; J Matthew McDonald; W K Alfred Yung; Howard Colman; Shiao Y Woo; Amy B Heimberger; Dima Suki; Michael D Prados; Susan M Chang; Fred G Barker; Jan C Buckner; C David James; Kenneth Aldape
Journal:  J Clin Oncol       Date:  2007-06-01       Impact factor: 44.544

9.  Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples.

Authors:  Koji Yoshimoto; Julie Dang; Shaojun Zhu; David Nathanson; Tiffany Huang; Rebecca Dumont; David B Seligson; William H Yong; Zhenggang Xiong; Nagesh Rao; Henrik Winther; Arnab Chakravarti; Darell D Bigner; Ingo K Mellinghoff; Steve Horvath; Webster K Cavenee; Timothy F Cloughesy; Paul S Mischel
Journal:  Clin Cancer Res       Date:  2008-01-15       Impact factor: 12.531

10.  A DNA aptamer recognizes the Asp f 1 allergen of Aspergillus fumigatus.

Authors:  Swee Yang Low; Jane E Hill; Jordan Peccia
Journal:  Biochem Biophys Res Commun       Date:  2009-06-21       Impact factor: 3.575

View more
  22 in total

Review 1.  Recent advances in understanding oligonucleotide aptamers and their applications as therapeutic agents.

Authors:  Khaled S Allemailem; Ahmad Almatroudi; Mohammed A Alsahli; Ghaiyda Talal Basfar; Faris Alrumaihi; Arshad Husain Rahmani; Amjad Ali Khan
Journal:  3 Biotech       Date:  2020-11-24       Impact factor: 2.406

2.  A U87-EGFRvIII cell-specific aptamer mediates small interfering RNA delivery.

Authors:  Xingmei Zhang; Huiyu Liang; Yan Tan; Xidong Wu; Shuji Li; Yusheng Shi
Journal:  Biomed Rep       Date:  2014-05-15

3.  Aptamer-Conjugated Chitosan-Anchored Liposomal Complexes for Targeted Delivery of Erlotinib to EGFR-Mutated Lung Cancer Cells.

Authors:  Fengqiao Li; Hao Mei; Xiaodong Xie; Huijuan Zhang; Jian Liu; Tingting Lv; Huifang Nie; Yu Gao; Lee Jia
Journal:  AAPS J       Date:  2017-02-23       Impact factor: 4.009

Review 4.  RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials.

Authors:  Eunice L Lozada-Delgado; Nilmary Grafals-Ruiz; Pablo E Vivas-Mejía
Journal:  Life Sci       Date:  2017-08-31       Impact factor: 5.037

Review 5.  [Research advances in the role of aptamers in the diagnosis and targeted therapy of pediatric cancer].

Authors:  Yi-Bin Zhang; Yan-Peng Wang; Jing Liu
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2018-05

6.  Target-specific delivery of doxorubicin to human glioblastoma cell line via ssDNA aptamer.

Authors:  Abdullah Tahir Bayrac; Oya Ercan Akca; Fusun Inci Eyidogan; Huseyin Avni Oktem
Journal:  J Biosci       Date:  2018-03       Impact factor: 1.826

Review 7.  Aptamer-mediated selective delivery of short RNA therapeutics in cancer cells.

Authors:  Carla Lucia Esposito; Silvia Catuogno; Vittorio de Franciscis
Journal:  J RNAi Gene Silencing       Date:  2014-10-30

8.  Selection and characterization of DNA aptamer against glucagon receptor by cell-SELEX.

Authors:  Guodong Wang; Jun Liu; Ke Chen; Yiling Xu; Bo Liu; Jie Liao; Lei Zhu; Xiaoxiao Hu; Jianglin Li; Ying Pu; Wen Zhong; Ting Fu; Huixia Liu; Weihong Tan
Journal:  Sci Rep       Date:  2017-08-03       Impact factor: 4.379

Review 9.  Aptamers and Glioblastoma: Their Potential Use for Imaging and Therapeutic Applications.

Authors:  Emma M Hays; Wei Duan; Sarah Shigdar
Journal:  Int J Mol Sci       Date:  2017-11-30       Impact factor: 5.923

10.  Aptamer-conjugated PEGylated quantum dots targeting epidermal growth factor receptor variant III for fluorescence imaging of glioma.

Authors:  Jiaze Tang; Ning Huang; Xiang Zhang; Tao Zhou; Ying Tan; Jiangli Pi; Li Pi; Si Cheng; Huzhi Zheng; Yuan Cheng
Journal:  Int J Nanomedicine       Date:  2017-05-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.